Stay updated on Safety of Doxorubicin & Pembrolizumab in Sarcoma Clinical Trial
Sign up to get notified when there's something new on the Safety of Doxorubicin & Pembrolizumab in Sarcoma Clinical Trial page.

Latest updates to the Safety of Doxorubicin & Pembrolizumab in Sarcoma Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedThe page revision header was updated from v3.4.3 to v3.5.0.SummaryDifference0.1%

- Check21 days agoChange DetectedPage revision updated to v3.4.3; the previous revision v3.4.2 was superseded.SummaryDifference0.1%

- Check28 days agoNo Change Detected
- Check50 days agoChange DetectedRevision: v3.4.2 was added and an older funding/operating-status notice was removed; these are minor administrative updates that do not affect the study content or how you interact with the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check57 days agoChange DetectedAdded a government funding lapse notice about data currency and updated the page revision from v3.4.0 to v3.4.1.SummaryDifference0.4%

- Check64 days agoChange DetectedAdded a 'Show glossary' option and updated the study record to display 'Last Update Submitted that Met QC Criteria' with revision v3.4.0. Removed the older label 'Last Update Submitted that met QC Criteria', adjusted capitalization of 'No FEAR Act Data' to 'No FEAR Act data', and updated the revision from v3.3.4 to v3.4.0.SummaryDifference0.2%

- Check78 days agoChange DetectedPage revision history updated: Revision v3.3.4 added and Revision v3.3.3 removed.SummaryDifference0.1%

Stay in the know with updates to Safety of Doxorubicin & Pembrolizumab in Sarcoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Safety of Doxorubicin & Pembrolizumab in Sarcoma Clinical Trial page.